key: cord-0943450-j2lxcn2r
authors: Haggenburg, Sabine; Lissenberg-Witte, Birgit I.; van Binnendijk, Rob S.; den Hartog, Gerco; Bhoekhan, Michel S.; Haverkate, Nienke J.E.; de Rooij, Dennis M.; van Meerloo, Johan; Cloos, Jacqueline; Kootstra, Neeltje A.; Wouters, Dorine; Weijers, Suzanne S.; van Leeuwen, Ester M.M.; Bontkes, Hetty J.; Tonouh-Aajoud, Saïda; Heemskerk, Mirjam H.M.; Sanders, Rogier W.; Roelandse-Koop, Elianne; Hofsink, Quincy; Groen, Kaz; Cetinel, Lucia; Schellekens, Louis; den Hartog, Yvonne M.; Toussaint, Belle; Kant, Iris M.J.; Graas, Thecla; de Pater, Emma; Dik, Willem A.; Engel, Marije D.; Pierie, R. Cheyenne N.; Janssen, Suzanne R.; van Dijkman, Edith; Poniman, Meliawati; Burger, Judith A.; Bouhuijs, Joey H.; Smits, Gaby; Rots, Nynke Y.; Zweegman, Sonja; Kater, Arnon P.; van Meerten, Tom; Mutsaers, Pim G.N.J.; van Doesum, Jaap A.; Broers, Annoek E.C.; van Gils, Marit J.; Goorhuis, Abraham; Rutten, Caroline E.; Hazenberg, Mette D.; Nijhof, Inger S.
title: Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
date: 2022-02-05
journal: Blood Adv
DOI: 10.1182/bloodadvances.2021006917
sha: e2cce791d35cc92013651927059fc53c2df46634
doc_id: 943450
cord_uid: j2lxcn2r

Vaccination guidelines for patients treated for hematological diseases are typically conservative. Given their high risk for severe coronavirus infectious disease 2019 (COVID-19) it is important to identify those patients that benefit from vaccination. We prospectively quantified serum IgG antibodies to spike subunit 1 (S1)antigensduring and after 2-dose mRNA-1273 (Spikevax/Moderna) vaccination in hematology patients. Obtaining S1 IgG≥300 binding antibody units (BAU)/mlwas considered adequate as it represents the lower level of S1 IgG concentration obtained in healthy individuals andit correlates with potent virus neutralization. Selected patients (n=723) were severely immunocompromised due to their disease or treatment thereof. Nevertheless, more than 50% of patients obtained S1 IgG ≥300 BAU/ml after 2-dose mRNA-1273. All patients with sickle cell disease or chronic myeloid leukemia obtained adequate antibody concentrations.Around 70% ofpatients with chronic graftversushostdisease (GvHD), multiple myeloma, or untreated chronic lymphocytic leukemia (CLL) obtained S1 IgG≥300 BAU/ml.Ruxolitinib or hypomethylating therapy but not high-dose chemotherapy blunted responses in myeloid malignancies. Responses inlymphoma patients, CLL patients on ibrutinib, and chimeric antigen receptor T cell recipients were low.The minimal time-interval after autologous hematopoietic cell transplantation (HCT) to reach adequate concentrations was <2 months for multiple myeloma, 8 months for lymphoma, and 4-6 months after allogeneic HCT.Serum IgG4, absolute B and NK cell number and number of immunosuppressants predicted S1 IgG ≥300 BAU/ml. Hematology patients on chemotherapy, shortly after HCT, or with chronic GvHD should not be precluded from vaccination. Netherlands Trial Register NL9553.

Since the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic it has become apparent that patients with hematologic diseases are at the highest risk for severe coronavirus disease 2019 (COVID- 19) , COVID-19-related death, and persistent viral shedding. [1] [2] [3] [4] In a large population-based study including over 17 million residents of England it was demonstrated that the mortality risk of SARS-CoV-2 infection in patients diagnosed with a hematologic malignancy in the past 5 years was more than 2.5-fold higher compared to individuals who had never been diagnosed with a malignant hematologic condition. 1 Mortality in patients with sickle cell disease was 5% compared to 0% in a matched cohort of healthcare professionals. 2 In early 2021, the Dutch government decided to prioritize COVID-19 vaccination in immunocompromised individuals, including patients with hematologic conditions. Given the pressure on the health care system at that time in the pandemic and the urgent need to protect as many individuals as possible, it was decided to vaccinate all patients, irrespective of current disease or treatment status.

This allowed us to prospectively measure the immunogenicity of mRNA-1273 (Moderna/Spikevax) vaccination in those patients that are generally considered too immunocompromised to benefit from vaccination and in whom vaccinations are often postponed until (later) after treatment, such as patients currently receiving, or just after, (immuno-)chemotherapy, early after transplantation, or after CD19 chimeric antigen receptor (CAR) T cell therapy, and in patients receiving novel, targeted therapies. 5, 6 By quantifying antibody concentrations against the WHO standard 7 we were able to identify those patients that despite their underlying condition mounted an adequate antibody response after mRNA-1273 vaccination. Our results demonstrate that in the midst of the pandemic, COVID-19 vaccination should not be postponed in hematology patients, even when under active or shortly after (immuno-)chemotherapy or cell therapy.

In this prospective, observational multicenter cohort study we included 723 adult hematology patients, classified into 17 different pre-defined cohorts based on their diagnosis and treatment status (Table 1; supplemental Table 1 ). Patient cohorts were defined based on relevance for the hematology practice, e.g. disease incidence (CLL, multiple myeloma) and knowledge gap (less often studied agents in the context of vaccination or often excluded treatment groups), with the aim to cover benign, lymphoid and myeloid diseases. Inclusion criteria were age ≥18 years, a diagnosis of lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative disease (MPN), sickle cell disease, AND receiving immuno-chemotherapy or having received such therapy preferably 6 months but maximally 12 months prior to vaccination, or receive targeted agents, or have received autologous or allogeneic hematopoietic cell transplantation (HCT) preferably 6 months but maximally 12 months prior to vaccination, or having received CD19-directed chimeric antigen receptor (CAR) T cell therapy. All these patients are considered immunocompromised, which is also reflected by their increased risk of COVID-19 related death. 1 Exclusion criteria included unwilling or unable to give informed consent, known allergy to one of the components of the vaccine, and a life expectancy of < 12 months. Prior infection with SARS-CoV-2 was not an exclusion criterion because the expected seroprevalence was below 5% (because of the stringent isolation measures in this patient population), and a test-first-strategy for seroprevalence would seriously hamper the speed of vaccination roll-out, whereas vaccination of seropositive patients was indicated nonetheless, according to the national vaccination guidelines. All participants received 2 doses of mRNA-1273 28 days apart ( Figure   1a ). Study protocols were approved by the Institutional Review Board of the Amsterdam UMC and participating centers. All patients provided written informed consent prior to study onset.

Pre-vaccination baseline leukocyte count, humoral and cellular immune parameters including quantitative assessment of lymphocytes, B, T and NK cell numbers and serum IgM, IgG and IgG subtypes 1-4, demographic parameters and medical history including comorbidities and concomitant medication were collected prospectively prior to each vaccination and 28 days after the 2 nd vaccination ( Figure 1a) . Clinical data were collected via standardized case report forms (CRF).

Humoral responses (IgG) against S1, receptor binding domain (RBD) and nucleocapsid (N) antigen domains of SARS-CoV-2 were determined quantitatively and centrally, using a beadbased multiplex immune assay (MIA). 8 SARS-CoV-2 binding antibody concentration was calibrated against the first serum standard for COVID-19 (20/136), as provided by the National Institute for Biological Standards Control (NIBSC), also recommended by the World Health Organization (WHO) to define specific serum antibody concentrations in an international perspective. [7] [8] [9] Seroconversion was defined as obtaining an S1 IgG concentration >10 BAU/ml, and an adequate vaccine response as S1 IgG 300 BAU/ml, the IgG concentration that met a PRNT50 (plaque reduction neutralization titer) of 40 or higher in 2 independent prospective Dutch mRNA-1273 vaccination cohorts. [10] [11] [12] [13] Reference antibody levels were extracted from the PIENTER cohort, 14 a nation-wide surveillance cohort with >3000 randomly selected Dutch citizens between 2-90 years of age that periodically provide a self-collected fingerstick blood sample and complete an online questionnaire.

From this cohort we selected all age-matched participants who had received a 2 nd dose of mRNA-1273 14-61 days prior to blood sampling (supplemental Table 2 ). To test antibody neutralization activity, we generated lentiviral-based pseudoviruses expressing the SARS-CoV-2 wild type variant (D614G) and determined the 50% inhibitory dose (ID 50 ) as the dilution of plasma with a 50% reduction of infection using HEK293T-ACE2 cells in all patients with S1 IgG 50 -300 BAU/ml and in a random selection of patients with S1 IgG 300 BAU/ml (supplemental Table 3 ). 15 SARS-CoV-2 pseudovirus neutralization correlated significantly with authentic SARS-CoV-2 neutralization as measured by PRNT or VNT. 15 

We aimed to include n=50 patients per subgroup to estimate S1 IgG 300 BAU/ml titers with a precision between 7 (at 0 or 100%) and 29% (at 50%) for Clopper-Pearson (exact) 95% confidence intervals (CI). Differences between groups and timepoints were analyzed with Mann-Whitney U and Wilcoxon Signed rank tests, respectively. Univariable and multivariable logistic regression models were used to identify factors associated with S1 IgG 300 BAU/ml 4 weeks after the 2 nd vaccination. Factors tested include pre-vaccination baseline leukocyte count, humoral and cellular immune parameters including lymphocyte, B, T and NK cell numbers, serum IgM, IgG and IgG subtypes 1-4, demographic parameters and immunosuppressive therapies. Multivariable models were built including all patients irrespective of cohort using a stepwise forward selection procedure (p-value for entry 0.05) with all univariable significant demographic, therapy-related and immunologic parameters, first as part of their subcategory of parameter, followed by a multivariable analysis of all significant parameters together. A sensitivity analysis was performed for the last model by excluding patients with untreated CLL. Pearson correlation was calculated between serum S1

IgG and in vitro pseudovirus neutralization after 10 The linearity assumption for continuous parameters in the logistic regression models were investigated by dividing the parameter in quartiles, parameters violating the linearity assumption were categorized in clinical relevant groups. The aim of this observational study is to identify those patients that respond sufficiently to COVID-19 vaccination. Due to the observational and descriptive nature of this study, there was no formal hypothesis testing framework.

A total of 723 patients were included, 695 of whom were available for analysis after completion of the vaccination schedule ( Figure 1b ; Table 1 ). Thirty-one study participants had sickle cell disease and were using hydroxyurea. All other participants had been diagnosed with a hematologic malignancy and were receiving or had recently received targeted therapy, tyrosine kinase inhibitor treatment, hypomethylating therapy, (immune) chemotherapy with or without HCT or CD19-directed CAR T cell therapy. Median S1 and RBD binding antibody concentrations increased significantly after 2 mRNA-1273 vaccinations, but overall remained significantly lower than the reference population ( (Table 1; supplemental Table 4 ). As they were primed for SARS-CoV-2 before vaccination, they had better S1 IgG responses than previously uninfected patients and obtained median S1 IgG concentrations comparable to those obtained in healthy individuals (Figure 2a ). They were excluded from further analyses. The majority (70%) of previously uninfected participants reached seroconversion (S1 IgG >10 BAU/ml), and 55% obtained S1 IgG 300 BAU/ml (Figure 2a; supplemental Table 5 ). Thirty percent of previously uninfected patients did not seroconvert at all. The correlation between serum S1 IgG and in vitro pseudovirus neutralization was strong (r=0.85; p<0.001; Figure 2b ).

In the 5 months after completion of the vaccination schedule (from 28 days after the 2 nd vaccination onwards), 17 (out of 723) patients tested SARS-CoV-2 positive. Seven of these patients received antibody therapy, either convalescent plasma (n=2) or casirivimab/imdevimab (n=5). All 17 patients experienced symptomatic infection, 3 patients required hospital care, 2 of which at the ICU. All 3 hospitalized patients were non-responders (S1 IgG< 10 BAU/ml). None of the study participants died because of COVID-19.

Median S1 IgG increased significantly in all cohorts after 2 doses mRNA-1273 ( Figure 3 ). An antibody concentration 300 BAU/ml was obtained in 96% of patients with sickle cell disease on hydroxyurea therapy, in 100% of patients with CML on tyrosine kinase inhibitor (TKI) therapy, and in 94% of patients with AML or high-risk MDS on or < 12 months after high dose chemotherapy ( Figure 3 ; supplemental Table 5 ). S1 IgG 300 BAU/ml was also observed in more than half of patients with multiple myeloma on 1 st line remission-induction therapy (52%), on daratumumab-containing therapy (69%), on immunomodulatory imide drugs (ImiDs, 77%), or within 9 months after high-dose melphalan (HDM) and autologous HCT (89%), in patients with untreated CLL (70%), and in allogeneic HCT recipients with chronic GvHD (69%). Less than half of patients with myeloproliferative disease on ruxolitinib (49%), with AML or high-risk MDS on hypomethylating therapy (41%), with lymphoma early after BEAM (carmustine, etoposide, cytarabine, melphalan) and autologous HCT (33%), patients shortly after allogeneic HCT (33%), and patients with CLL on ibrutinib (27%) obtained S1 IgG 300 BAU/ml. Only few patients with B-non Hodgkin lymphoma (NHL) on (0%) or within 12 months after (26%) rituximab monotherapy or rituximab-containing immunochemotherapy, and of CD19-directed CAR T cell therapy recipients (11%) obtained S1 IgG 300 BAU/ml ( Figure 3 ; supplemental Table 5 ). The few responding patients in the CAR-T cell cohort all had normal B cell numbers. Individual RBD binding antibody concentrations showed similar dynamics over time (not shown).

Of the immunologic factors, demographic parameters and immunosuppressive medications identified to be associated with obtaining S1 IgG 300 BAU/ml in the univariable models, several remained significant in a multivariable model per subcategory of variables ( Figure 4a) and in an overall model (Figure 4b ; supplemental Table 6 ). In the overall model, and across cohorts, age correlated significantly with vaccination response (odds ratio (OR) 0.87 per 5year increase; 95% CI 0.79-0.96; p=0.005). IgG4 concentration (OR 1.8 per g/L; CI 1.1-3.1; p=0.019) and absolute number of NK cells higher than the upper limit of normal (OR 8.4; CI 2.9-24.4; p<0.001) were associated with obtaining S1 IgG 300 BAU/ml. Lower than normal numbers of B cells (<0.1x10 9 /L) decreased odds to obtain S1 IgG 300 BAU/ml (OR 0.25; CI 0.15-0.42; p<0.001). Higher than normal number of B cells (>0.5x10 9 /L) was also associated with decreased odds to obtain S1 IgG 300 BAU/ml (OR 0.35; CI 0.18-0.67; p<0.001), but this association was lost when patients with CLL were excluded (OR 1.15; CI 0.40-3.28;

supplemental Table 6 ). Absolute CD3 and CD8 T cell numbers were significantly associated with obtaining S1 IgG 300 BAU/ml when tested per subcategory of parameters but not in the overall model. The use of rituximab (OR 0.24; CI 0.10-0.57; p=0.001), the Bcl2 inhibitor venetoclax (OR 0.11; CI 0.019-0.63; p=0.013) and CD19-directed CAR T cell therapy (OR 0.16; CI 0.057-0.48; p=0.001) was negatively associated with obtaining S1 IgG 300 BAU/ml. This also applied to the number of immunosuppressants used (1 to 2 immunosuppressants: OR 0.45; CI 0.28-0.73; >2: OR 0.25; CI 0.10-0.64; p=0.001)). The use of specific immunosuppressants such as mycophenolic acid, calcineurin inhibitors, corticosteroids or the jak2 inhibitor ruxolitinib was not significantly associated with the odds to obtain S1 IgG 300 BAU/ml whether analyzed in the overall model or per patient cohort (allogeneic HCT, chronic GvHD and CLL on ibrutinib; supplemental Table 7 ). Lenalidomide or pomalidomide treatment and the use of TKI on the other hand was associated with higher odds to obtain S1 IgG 300 BAU/ml (OR 3.5; CI 1.8-6.7; p<0.001 and OR 2.7; CI 1.1-7.1; p0.038, respectively; Figure 4b ).

Within cohorts, time after cessation of rituximab, after autologous HCT or after allogeneic HCT was not significantly associated with the odds to obtain sufficient S1 IgG concentrations (lymphoma: p=0.069; multiple myeloma: p=0.98; allogeneic HCT: p=0.272; supplemental Table 7 ). Nevertheless, a time interval after which sufficient S1 IgG concentrations were reached could be identified for each cohort. In patients with lymphoma, median S1 IgG 300 BAU/ml were not reached before 8 months after cessation of rituximab therapy and after autologous HCT (Figure 5a ), while in multiple myeloma patients sufficient S1 IgG concentrations were obtained immediately after autologous HCT (Figure 5b ). In allogeneic HCT recipients, a median S1 IgG 300 BAU/ml was not reached before 4-6 months after transplantation (Figure 5c ). In all groups, numbers of circulating B cells did not need to be normalized to obtain S1 IgG 300 BAU/ml ( Figure 5 ).

At the time COVID-19 vaccines became available, vaccination guidelines in hematology patients under active treatment were conservative, due to the paucity of vaccine response data and the many uncertainties regarding the immunocompetence of these patients. 5, 6 Our study is unique in that it was designed to specifically include severely immunocompromised hematology patients during or shortly after treatment or HCT, for whom vaccinations are often deemed futile. Moreover, we performed a quantitative analysis of SARS-CoV-2 binding antibody concentrations, calibrated against the WHO standard, 7,10-13,15 to identify those patients who despite their immunodeficiency did obtain adequate antibody concentrations.

In collaboration with a number of other prospective cohort studies on the immunogenicity of COVID-19 vaccination among immunocompromised and healthy individuals conducted in the Netherlands, we set an S1 IgG concentration of 300 BAU/ml as the lower threshold of an adequate COVID-19 vaccine response. 9, 11, [13] [14] [15] [16] It is interesting to note that a lower threshold of 264 BAU/ml was very recently, in an independent British cohort, estimated to correspond to a vaccine efficacy against symptomatic COVID-19 of 80%. 7 Even though we included only patients considered to be severely immunocompromised, 70% demonstrated significant increases in antibody concentrations and more than 50% obtained adequate antibody concentrations. In particular patients with sickle cell disease, CML on TKI, AML and high-risk MDS on or < 12 months after high-dose chemotherapy, multiple myeloma on ImiDS or daratumumab therapy, untreated CLL patients and patients with chronic GvHD had higher odds to obtain adequate S1 IgG concentrations than anticipated. Serum S1 IgG correlated strongly with in vitro antibody mediated virus neutralization, confirming data obtained from studies in healthy individuals, patients with kidney disease and oncology patients. 11, 13, 17, 18 In general, S1 IgG responses were higher in our study than reported previously. For example, seroconversion was reached in 83% of untreated CLL patients, compared to 55% in a cohort of therapy-naive CLL patients vaccinated with BNT162b2. 19 Apart from the differences in vaccination schedule and age, which was lower in our cohort (median age 64 vs 71 years), type of vaccine is a possible determining factor. All participants in our study received mRNA-1273, which induces higher antibody concentrations than other vaccines. [20] [21] [22] [23] Whether this corresponds to better protection against severe COVID-19 remains to be determined.

Vaccination guidelines for autologous HCT recipients do not typically differentiate between patient groups. 5 Our data demonstrate, however, that vaccine immunogenicity after autologous HCT depends on the underlying hematologic condition and/or treatment. In multiple myeloma patients, adequate antibody responses were reached immediately after HCT, while lymphoma patients did not obtain adequate S1 IgG titers before at least 8 months after HCT, similar as observed in B-NHL patients after cessation of rituximabcontaining therapy. These differences are probably related to differences in the degree of B cell depletion between cohorts, that was much less stringent in multiple myeloma patients.

Of note, our results demonstrate that also low numbers of B cells can produce adequate levels of antibodies. In multivariable analyses, IgG4 concentration and absolute B and NK cell numbers predicted S1 IgG responses. Not only lower-than normal B cell numbers was associated with blunted antibody responses, also higher-than-normal B cell numbers reduced odds to obtain sufficient S1 IgG concentrations. As this correlation was no longer significant when CLL patients were excluded from the analysis this is most likely related to CLL associated reduced numbers of normal B cells and/or immune paralysis. 24 SARS-CoV-2 vaccination responses were better in patients using the immunomodulator lenalidomide, as demonstrated previously for pneumococcal vaccination, 25 and in CML patients using TKI. The latter is in contrast to previous reports demonstrating reduced immunogenicity of pneumococcal vaccination during TKI therapy, 26 which may be related to the distinctive pathways of immunity induced by mRNA vaccines compared to T cell independent polysaccharide vaccines. 27 Together these data suggest that concerted immune responses that may include the help of cytokine producing NK cells yield the best antibody concentrations after vaccination. 27, 28 Almost 50% of patients did not reach S1 IgG 300 BAU/ml. Many of these patients nevertheless demonstrated a clear increase in antibody concentrations after each vaccination, suggesting that antibody responses can be further enhanced with one or more extra vaccinations. [29] [30] [31] Ideally, such vaccination schedules are guided by S1 IgG concentrations, and we are currently testing the feasibility of such an approach. Other important questions presently under investigation by us and others refer to the functionality of T and NK cells and the durability and functionality of antibody and B cell recall responses, in particular in patients with a reduced B cell repertoire, patients with quantitatively or qualitatively insufficient T cell help and patients who are receiving daratumumab to deplete malignant plasma cells. Importantly, blunted antibody responses in rituximab-treated rheumatology patients did not rule out the generation of T cell immunity against SARS-CoV-2, 32,33 but true vaccine efficacy in B cell depleted patients remains to be determined. We did observe breakthrough infections after completion of the primary vaccination schedule, but none of our study participants died of COVID-19. While this may seem encouraging, it is important to emphasize that our study was not powered to investigate vaccine effectiveness. Indeed, an English population based study demonstrated persistently increased risk of COVID-related death for patients with hematologic conditions despite vaccination. 34 It is advised to consider SARS-CoV-2 monoclonal antibody therapy for patients with impaired humoral immunity who tested positive for SARS-CoV-2. 35 Table 2 . The most important message is that immunocompromised hematology patients should not be precluded from vaccination, even though full antibody-mediated protection cannot be guaranteed for all. Figure 2 . S1 binding antibody concentration and neutralisation. A. IgG S1 concentration for each timepoint. Red and black: previously uninfected patients (U); orange and grey:

previously infected patients (I). Dotted lines indicate seroconversion (S1 IgG >10 BAU/ml) and sufficient S1 IgG concentration (≥300 BAU/ml). Asterix: p<0.05. B. Correlation of IgG S1

concentration and pseudovirus neutralization (r=0.85; p<00.1).

IgG S1 concentration over time for each patient. Thin lines depict previously uninfected patients (red) and previously infected patients (orange); thick lines indicate the median IgG S1 concentrations. Dotted lines specify seroconversion (S1 IgG >10 BAU/ml) and sufficient S1 IgG concentration (≥300 BAU/ml). Asterix: p<0.05. IgG S1 (BAU/ml) 10 

Factors associated with COVID-19-related death using OpenSAFELY

Comparison of the clinical course of COVID-19 infection in sickle cell disease patients with healthcare professionals

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with

Transmissibility and viral replication of SARS-COV-2 in immunocompromised patients

Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia

Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence

SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees

COVID-19 vaccination: the VOICE for patients with cancer

COVID-19 vaccination in patients receiving chemotherapy , immunotherapy , or chemoimmunotherapy for solid tumours : a prospective , multicentre , non-inferiority trial

The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant

The RECOVAC Immune-response Study : The Immunogenicity , Tolerability , and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease , on Dialysis , or Living With a Kidney Transplant

Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave

Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination

Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study

Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients with Hematologic Malignancies: A Need for Vigilance in the Postmasking Era

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Comparison of SARS-CoV-2

Antibody Response following Vaccination with BNT162b2 and mRNA-1273

Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine

SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA-versus vector-based vaccination in the general Dutch population. medRxiv

Secondary Immunode fi ciency in Hematological Malignancies : Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia

Lenalidomide-induced immunomodulation in multiple myeloma: Impact on vaccines and antitumor responses

Tyrosinekinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling

A guide to vaccinology: from basic principles to new developments

Natural Killer Cell Regulation of B Cell Responses in the Context of Viral Infection

Randomized Trial of a Third Dose of mRNA-1273

Vaccine in Transplant Recipients

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT

Cellular And Humoral Immune Responses after Three Doses of BNT162b2 mRNA SARS-Cov-2 Vaccine in Kidney Transplant

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cellmediated immunity

Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination : national prospective cohort study

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

The authors would like to extend their deepest gratitude to all patients, colleagues, students and volunteers from participating institutes, the Netherlands Cancer Registry and the National Institute for Public Health and the Environment who made this study possible. This study was financially supported by the Dutch Research Council (NWO ZonMW, grant